Aravive (ARAV) Competitors $0.04 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSustainabilityTrends ARAV vs. SNSE, CDT, AWH, IPA, INDP, TSBX, PHXM, KPRX, MBIO, and SNTIShould you be buying Aravive stock or one of its competitors? The main competitors of Aravive include Sensei Biotherapeutics (SNSE), Conduit Pharmaceuticals (CDT), Aspira Women's Health (AWH), ImmunoPrecise Antibodies (IPA), Indaptus Therapeutics (INDP), Turnstone Biologics (TSBX), PHAXIAM Therapeutics (PHXM), Kiora Pharmaceuticals (KPRX), Mustang Bio (MBIO), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. Aravive vs. Sensei Biotherapeutics Conduit Pharmaceuticals Aspira Women's Health ImmunoPrecise Antibodies Indaptus Therapeutics Turnstone Biologics PHAXIAM Therapeutics Kiora Pharmaceuticals Mustang Bio Senti Biosciences Sensei Biotherapeutics (NASDAQ:SNSE) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends. Is SNSE or ARAV more profitable? Aravive's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sensei BiotherapeuticsN/A -53.86% -46.91% Aravive N/A N/A N/A Do analysts recommend SNSE or ARAV? Sensei Biotherapeutics currently has a consensus price target of $4.33, suggesting a potential upside of 824.15%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Aravive.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of SNSE or ARAV? 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 22.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, SNSE or ARAV? Sensei Biotherapeutics has higher earnings, but lower revenue than Aravive. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensei BiotherapeuticsN/AN/A-$34.10M-$1.19-0.39Aravive$9.14M0.32-$76.32M-$0.96-0.04 Does the MarketBeat Community favor SNSE or ARAV? Aravive received 77 more outperform votes than Sensei Biotherapeutics when rated by MarketBeat users. However, 79.41% of users gave Sensei Biotherapeutics an outperform vote while only 62.28% of users gave Aravive an outperform vote. CompanyUnderperformOutperformSensei BiotherapeuticsOutperform Votes2779.41% Underperform Votes720.59% AraviveOutperform Votes10462.28% Underperform Votes6337.72% Does the media refer more to SNSE or ARAV? In the previous week, Sensei Biotherapeutics had 4 more articles in the media than Aravive. MarketBeat recorded 4 mentions for Sensei Biotherapeutics and 0 mentions for Aravive. Sensei Biotherapeutics' average media sentiment score of 0.60 beat Aravive's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Sensei Biotherapeutics Positive Aravive Neutral SummaryAravive beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricAravivePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.044.9789.5613.60Price / Sales0.32371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book0.2210.306.976.33Net Income-$76.32M$153.61M$119.04M$225.93M7 Day PerformanceN/A-1.73%-1.78%-0.96%1 Month PerformanceN/A-7.26%-3.59%1.06%1 Year PerformanceN/A31.10%31.64%26.59% Aravive Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVAravive0.8247 of 5 stars$0.04flatN/AN/A$2.95M$9.14M-0.0420High Trading VolumeSNSESensei Biotherapeutics4.8056 of 5 stars$0.47-5.8%$4.33+824.1%-20.0%$11.79MN/A0.0040News CoverageCDTConduit PharmaceuticalsN/A$0.12+32.8%N/A-92.8%$11.77MN/A0.003News CoverageGap UpHigh Trading VolumeAWHAspira Women's Health1.533 of 5 stars$0.73flat$4.40+502.7%-78.5%$11.72M$9.15M-0.64110Analyst ForecastGap UpIPAImmunoPrecise Antibodies2.0348 of 5 stars$0.40+2.5%$6.00+1,416.7%-72.2%$11.41M$18.16M0.0080INDPIndaptus Therapeutics2.7304 of 5 stars$1.05-1.0%$8.50+709.9%-48.7%$10.71MN/A0.006TSBXTurnstone Biologics3.2023 of 5 stars$0.46+0.1%$2.13+361.5%-84.8%$10.65M$19.31M0.0082PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049KPRXKiora Pharmaceuticals2.9909 of 5 stars$3.42+5.9%$10.00+192.4%-32.4%$10.26MN/A0.0010MBIOMustang Bio1.9408 of 5 stars$0.21-0.5%$2.00+862.0%-87.6%$9.93MN/A-0.13100SNTISenti Biosciences0.7453 of 5 stars$2.16+1.9%N/A-42.1%$9.91M$2.56M-0.144News Coverage Related Companies and Tools Related Companies SNSE Competitors CDT Competitors AWH Competitors IPA Competitors INDP Competitors TSBX Competitors PHXM Competitors KPRX Competitors MBIO Competitors SNTI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARAV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARAV Stock Alerts